multicancer platform
Signal-X
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity.
.jpg)
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable.
For our first test, Signal-C™, we identify the regions associated with colorectal cancer, including pre-cancerous adenomas, allowing us to detect the disease in its earliest stages – in many cases, before it progresses to cancer.
Starting from a deep knowledge of the disease, we have built a technological platform able to “read” the signal of cancer in blood.
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity.
Our first blood test, Signal-C, accurately detects colorectal cancer with a sensitivity of 92% and specificity of 97% (abstract presented at ASCO 2021).
Signal-C is also focused on detecting Advanced Adenoma; our first experiments show a sensitivity of 52% and a specificity of 90 (abstract presented at EACR 2021).
We are applying our multi-omics + computational biology + machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers, including pancreatic (“Signal-P”), liver (“Signal-L”), and gastric/stomach (“Signal-G”).
We presented proof of concept studies for various cancers with high accuracy, including for early stages (abstract presented at ESMO 2020)
We are driven forward by a vision of a future where cancer is curable.
Press releases
Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity
May 9, 2023
Press releases
Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity
May 9, 2023
Press releases
Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity
May 9, 2023
Press releases
New Data from Universal DX: Combining Copy Number Variation (CNV) with cfDNA Fragment Size Information Could Serve as Promising New Avenue for Early Detection of Colorectal Cancer (CRC)
Apr 17, 2023
Press releases
New Data from Universal DX: Combining Copy Number Variation (CNV) with cfDNA Fragment Size Information Could Serve as Promising New Avenue for Early Detection of Colorectal Cancer (CRC)
Apr 17, 2023
Press releases
New Data from Universal DX: Combining Copy Number Variation (CNV) with cfDNA Fragment Size Information Could Serve as Promising New Avenue for Early Detection of Colorectal Cancer (CRC)
Apr 17, 2023